Solanezumab Promising in Mild Alzheimer’s, But Program Still Very Risky: Analyst
Eli Lilly’s Alzheimer’s disease candidate solanezumab may offer potential as a treatment for milder forms of the disease, new detailed data reveal, but the company’s prospects are still flimsy, with odds of failure potentially exceeding more than 50 percent, one analyst says.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.